Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
3 Pre-clinical Research Results Presented at AACR 2024

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that it has presented the pre-clinical combination study results of its highly selective small molecule FGFR4 inhibitor irpagratinib (ABSK011) with oral presentation during AACR Annual Meeting 2024. In addition, Abbisko Therapeutics has also presented pre-clinical data of its innovative CSF-1R inhibitor pimicotinib (ABSK021) and oral small molecule PD-L1 inhibitor by posters.

This is a voluntary announcement made by the Company. The Group cannot guarantee that irpagratinib and pimicotinib will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, April 10, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko Therapeutics Presented 3 Pre-clinical Research Results with Oral and Poster Presentations at AACR 2024

On April 10, 2024, Abbisko Therapeutics announced that it has presented the pre-clinical combination study results of its highly selective small molecule FGFR4 inhibitor irpagratinib with oral presentation during AACR Annual Meeting 2024. In addition, Abbisko Therapeutics has also presented pre-clinical data of its innovative CSF-1R inhibitor pimicotinib and oral small molecule PD-L1 inhibitor by posters. As one of the most prestigious oncology conferences in the world, AACR 2024 conference was held in San Diego, USA from April 5 to 10, 2024.

Abbisko Therapeutics presentations in the AACR 2024:

Title: Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models

Oral presentation number: 1228
Session: Novel Antitumor Agents 1
Session date and time: April 7, 2024, 3:05 PM – 3:20 PM (PT)

Introductions:

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, ranking as the sixth most prevalent cancer and the third leading cause of death worldwide. Deregulation of FGF19-FGFR4 signaling accounts for roughly 30% of HCC and plays a pivotal role in driving HCC tumorigenesis. Irpagratinib (ABSK011) is a highly potent and selective FGFR4 inhibitor, with the potential to become a first-in-class or best-in-class FGFR4 inhibitor. It showed promising anti-tumor activity in an ongoing phase Ib clinical study, with an ORR of 40.7% observed in FGF19 overexpressed late line HCC patients in cohorts treated with BID regimens. To further expand the therapeutic potential of Irpagratinib, Abbisko Therapeutics carried out an array of preclinical translational studies, exploring the efficacy and mechanisms of combination treatments.

Conclusion:

In summary, these findings collectively illustrate very broad synergistic anti-tumor effects of Irpagratinib when combined with various other therapeutic agents. These results may pave the road for potential novel combinatory therapeutic strategies that could expand the utility of Irpagratinib and provide innovative and more effective therapies to HCC patients.

Title: CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of $KRAS^{G12C}$ inhibitors in preclinical non-small cell lung cancer mouse models

Session: Late-Breaking Research: Immunology 1
Location: Poster Section 54
Poster Board Number: 13
Session Date and Time: April 7, 2024, 1:30 PM – 5:00 PM (PT)
Poster Number: LB077

Introductions:

$KRAS^{G12C}$ is a common oncogenic driver in human cancers, particularly in KRAS-mutant non-small cell lung cancer (NSCLC). Tumor associated macrophages (TAMs) are enriched in KRAS-driven transgenic lung cancer models, and their depletion significant reduces tumor burden and improves survival. Sotorasib (AMG510), the first $KRAS^{G12C}$ inhibitor approved by FDA, has been found to increase macrophage levels in mouse model. CSF-1R inhibition depletes TAMs and reprograms tumor microenvironment (TME). Therefore, the combination of $KRAS^{G12C}$ and CSF-1R inhibitors may synergize to enhance anti-tumor efficacy. Pimicotinib (ABSK021) is a potential best-in-class small molecule inhibitor of CSF-1R in clinical development of multiple indications. Here, Abbisko conducted preclinical translational studies to explore the combined effects of $KRAS^{G12C}$ and CSF-1R inhibitors.

Conclusion:

For the first time, we demonstrate that the combined inhibition of $KRAS^{G12C}$ and CSF-1R leads to superior therapeutic efficacy in pre-clinical NSCLC mouse models. These results suggest a potential novel therapeutic regimen that could yield improved clinical benefit to patients.

Title: Cellular characterization of small molecule PD-L1 inhibitors reveal their novel mechanisms of action

Session: Experimental and Molecular Therapeutics
Location: Poster Section 27
Poster Board Number: 22
Session Date and Time: April 8, 2024, 9:00 AM – 12:30 PM (PT)
Poster Number: 2039

Introductions:

Immune checkpoint, including PD-1/L1, are key regulators of immune response and promising targets in cancer immunotherapy. Like anti-PD-1/L1 antibodies, small molecule PD-L1 inhibitors that have been discovered by us and others could also efficiently block PD-1 and PD-L1 interaction and exhibit anti-tumor efficacy in preclinical and clinically settings. In this study, we explore the cellular mechanism of small molecule PD-L1 inhibitors, unveiling their novel mechanisms of action in the regulation of PD-L1 and its functions.

Conclusion:

Taken together, these results for the first time revealed the distinctive mechanisms of our small molecule PD-L1 inhibitors. With their multi-layer inhibitory effects stemming from various mechanisms, small molecule PD-L1 inhibitors may offer potentially improved activities and an alternative therapeutic treatment for the cancer patients.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.